Glaukos Technologies Featured in Numerous Presentations at the 2020 American Society of Cataract and Refractive Surgery Virtual Annual Meeting - Seite 2

Case Series of Trabecular Micro-Bypass Stents Implanted Inferiorly in Combination with Cataract Surgery

• George R. Wandling Jr., MD
  Early Outcomes from a Real-World Study of Second-Generation Trabecular Micro-Bypass Stents (iStent inject) Combined with Cataract Surgery

• Blake K. Williamson, MD
  Early U.S. Experience with iStent inject Trabecular Micro-Bypass Implantation with Cataract Surgery

KEY CORNEAL HEALTH PRESENTATIONS:

• Miltiadis Balidis, PhD
  Transepithelial Customized Corneal Collagen Cross-Linking for Keratoconus

• Chunlei Liu, MD, PhD
  Comparison of One-Year Outcomes between SMILE Xtra and LASIK Xtra

• Julianne M. Matthews, MD, MPH
  How Long Does It Take for BCVA, Kmax, and Pachymetry to Return to Baseline after Corneal Collagen Cross-Linking for Keratoconus?

• Angelica Ortiz, MD
  Corneal Cross-Linking in Keratoconus Patients: One-Year Visual and Keratometric Outcomes

• Shreyas Ramamurthy, MD
  Comparative Study of Conventional Epithelium-Off Cross-Linking (CXL) versus High Fluence Transepithelial CXL with Supplemental Oxygen

• Borja Salvador-Culla, MD
  Continuous versus Pulsed Accelerated Cornea Cross-Linking to Arrest Progression of Corneal Ectasia: A Multicenter Study

• Gina Shetty, MD
  Corneal Cross-Linking (CXL) Outcomes in Children with Progressive Keratoconus

• Dian Yu, MD
  Early Evidence of Visual and Topographic Improvements Following Cross-Linking Procedure for Eyes with Keratoconus

Abstracts and full session details can be found at www.ascrs.org.

The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry. All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve or recommend the use of any products, devices or services.

Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS), which involves insertion of a micro-scale device from within the eye's anterior chamber through a small corneal incision. Glaukos’ MIGS devices are designed to reduce IOP by restoring the natural outflow pathways for aqueous humor. Glaukos received U.S. Food and Drug Administration (FDA) approval for its first-generation MIGS device, the iStent, in 2012. Its second-generation iStent inject, which received FDA approval in 2018, includes two stents preloaded in an auto-injection mechanism that facilitates stent insertion into multiple trabecular meshwork locations through a single corneal incision. The iStent inject is also approved in the European Union, Armenia, Australia, Brazil, Canada, Hong Kong, Singapore, South Africa and other international markets. Glaukos is pursuing FDA approval for additional MIGS surgical and sustained pharmaceutical therapy pipeline products, all of which are investigational in the United States.